Join
Live feed
·
PRReleasevia Quantisnow
ACELYRIN INC. logo

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
SLRN· ACELYRIN INC.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLRN (ACELYRIN INC.) and more on Quantisnow.